Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;28(3):213-227.
doi: 10.1007/s12022-017-9484-5.

Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours

Affiliations
Review

Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours

Alfred King-Yin Lam. Endocr Pathol. 2017 Sep.

Abstract

The fourth edition of the World Health Organization (WHO) classification of endocrine tumours contains substantial new findings for the adrenal tumours. The tumours are presented in two chapters labelled as "Tumours of the adrenal cortex" and "Tumours of the adrenal medulla and extra-adrenal paraganglia." Tumours of the adrenal cortex are classified as cortical carcinoma, cortical adenoma, sex cord stromal tumours, adenomatoid tumour, mesenchymal and stromal tumours (myelolipoma and schwannoma), haematological tumours, and secondary tumours. Amongst them, schwannoma and haematological tumours are newly documented. The major updates in adrenal cortical lesions are noted in the genetics of the cortical carcinoma and cortical adenoma based on the data from The Cancer Genome Atlas (TCGA). Also, a system for differentiation of oncocytoma from oncocytic cortical carcinoma is adopted. Tumours of the adrenal medulla and extra-adrenal paraganglia comprise pheochromocytoma, paraganglioma (head and neck paraganglioma and sympathetic paraganglioma), neuroblastic tumours (neuroblastoma, nodular ganglioneuroblastoma, intermixed ganglioneuroblastoma, and ganglioneuroma), composite pheochromocytoma, and composite paraganglioma. In this group, neuroblastic tumours are newly included in the classification. The clinical features, histology, associated pathologies, genetics, and predictive factors of pheochromocytoma and paraganglioma are the main changes introduced in this chapter of WHO classification of endocrine tumours. The term "metastatic pheochromocytoma/paraganglioma" is used to replace "malignant pheochromocytoma/paraganglioma." Also, composite pheochromocytoma and composite paraganglioma are now documented in separate sections instead of one. Overall, the new classification incorporated new data on pathology, clinical behaviour, and genetics of the adrenal tumours that are important for current management of patients with these tumours.

Keywords: Adrenal; Genetic; Pathology; Tumour; WHO.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Mod Pathol. 2014 Sep;27(9):1246-54 - PubMed
    1. Am J Surg Pathol. 1986 Nov;10(11):816-22 - PubMed
    1. Can Urol Assoc J. 2014 Mar-Apr;8(3-4):E132-6 - PubMed
    1. Endocr Pract. 2011 Jul-Aug;17 Suppl 3:2-7 - PubMed
    1. Kardiochir Torakochirurgia Pol. 2016 Sep;13(3):276-282 - PubMed

MeSH terms